JP2004528319A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004528319A5 JP2004528319A5 JP2002577823A JP2002577823A JP2004528319A5 JP 2004528319 A5 JP2004528319 A5 JP 2004528319A5 JP 2002577823 A JP2002577823 A JP 2002577823A JP 2002577823 A JP2002577823 A JP 2002577823A JP 2004528319 A5 JP2004528319 A5 JP 2004528319A5
- Authority
- JP
- Japan
- Prior art keywords
- sulfonyl
- pyridazin
- benzofuran
- chloro
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 pyrazinopyrazinyl Chemical group 0.000 claims 72
- 150000001875 compounds Chemical class 0.000 claims 27
- 239000000651 prodrug Substances 0.000 claims 24
- 229940002612 prodrug Drugs 0.000 claims 24
- 125000001424 substituent group Chemical group 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 13
- 125000001153 fluoro group Chemical group F* 0.000 claims 10
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 9
- 125000003226 pyrazolyl group Chemical group 0.000 claims 8
- 125000000335 thiazolyl group Chemical group 0.000 claims 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical compound OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 claims 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000002883 imidazolyl group Chemical group 0.000 claims 7
- 125000000842 isoxazolyl group Chemical group 0.000 claims 7
- 125000002971 oxazolyl group Chemical group 0.000 claims 7
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 6
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 6
- 125000002541 furyl group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000005956 isoquinolyl group Chemical group 0.000 claims 6
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims 6
- 125000005493 quinolyl group Chemical group 0.000 claims 6
- 125000003831 tetrazolyl group Chemical group 0.000 claims 6
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 6
- 125000001544 thienyl group Chemical group 0.000 claims 6
- 125000001425 triazolyl group Chemical group 0.000 claims 6
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 125000004244 benzofuran-2-yl group Chemical group [H]C1=C(*)OC2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 4
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 125000005554 pyridyloxy group Chemical group 0.000 claims 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- FXFPQPNUMWQRAO-UHFFFAOYSA-N 6-[(5-chloro-3-methyl-1-benzofuran-2-yl)sulfonyl]pyridazin-3(2h)-one Chemical compound O1C2=CC=C(Cl)C=C2C(C)=C1S(=O)(=O)C=1C=CC(=O)NN=1 FXFPQPNUMWQRAO-UHFFFAOYSA-N 0.000 claims 3
- 125000004647 alkyl sulfenyl group Chemical group 0.000 claims 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 2
- 125000004738 (C1-C6) alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 2
- DXMRTFOZJATGPZ-UHFFFAOYSA-N 3-[[3-methyl-5-(trifluoromethyl)-1-benzofuran-2-yl]sulfonyl]-1h-pyridazin-6-one Chemical compound O1C2=CC=C(C(F)(F)F)C=C2C(C)=C1S(=O)(=O)C=1C=CC(=O)NN=1 DXMRTFOZJATGPZ-UHFFFAOYSA-N 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- RBZSSTPBYFHRSR-UHFFFAOYSA-N 3-(1-benzofuran-2-ylsulfonyl)-1h-pyridazin-6-one Chemical compound N1C(=O)C=CC(S(=O)(=O)C=2OC3=CC=CC=C3C=2)=N1 RBZSSTPBYFHRSR-UHFFFAOYSA-N 0.000 claims 1
- WFJJYKJYGCGPFS-UHFFFAOYSA-N 3-(1-benzylindol-5-yl)sulfonyl-1h-pyridazin-6-one Chemical compound N1C(=O)C=CC(S(=O)(=O)C=2C=C3C=CN(CC=4C=CC=CC=4)C3=CC=2)=N1 WFJJYKJYGCGPFS-UHFFFAOYSA-N 0.000 claims 1
- YVEUDWZQMUISKP-UHFFFAOYSA-N 3-(1-methylindol-2-yl)sulfonyl-1h-pyridazin-6-one Chemical compound C=1C2=CC=CC=C2N(C)C=1S(=O)(=O)C=1C=CC(=O)NN=1 YVEUDWZQMUISKP-UHFFFAOYSA-N 0.000 claims 1
- HXNAGYMCTAINEA-UHFFFAOYSA-N 3-(1h-indol-2-ylsulfonyl)-1h-pyridazin-6-one Chemical compound N1C(=O)C=CC(S(=O)(=O)C=2NC3=CC=CC=C3C=2)=N1 HXNAGYMCTAINEA-UHFFFAOYSA-N 0.000 claims 1
- ZCHJRGKQXZDDOT-UHFFFAOYSA-N 3-(1h-indol-3-ylsulfonyl)-1h-pyridazin-6-one Chemical compound N1C(=O)C=CC(S(=O)(=O)C=2C3=CC=CC=C3NC=2)=N1 ZCHJRGKQXZDDOT-UHFFFAOYSA-N 0.000 claims 1
- NQJFBHVHPOEWLC-UHFFFAOYSA-N 3-(3,4,4a,5-tetrahydro-2h-quinolin-1-ylsulfonyl)-1h-pyridazin-6-one Chemical compound N1C(=O)C=CC(S(=O)(=O)N2C3=CC=CCC3CCC2)=N1 NQJFBHVHPOEWLC-UHFFFAOYSA-N 0.000 claims 1
- FFQYWMOJPDVLPU-UHFFFAOYSA-N 3-(3-methylindol-1-yl)sulfonyl-1h-pyridazin-6-one Chemical compound C12=CC=CC=C2C(C)=CN1S(=O)(=O)C=1C=CC(=O)NN=1 FFQYWMOJPDVLPU-UHFFFAOYSA-N 0.000 claims 1
- LCVXWZKNHISEPA-UHFFFAOYSA-N 3-(5h-[1,3]dioxolo[4,5-f]indol-6-ylsulfonyl)-1h-pyridazin-6-one Chemical compound N1C(=O)C=CC(S(=O)(=O)C=2NC3=CC=4OCOC=4C=C3C=2)=N1 LCVXWZKNHISEPA-UHFFFAOYSA-N 0.000 claims 1
- NTJWJLZMOKBOFA-UHFFFAOYSA-N 3-[(3,5-dimethyl-1-benzofuran-2-yl)sulfonyl]-1h-pyridazin-6-one Chemical compound O1C2=CC=C(C)C=C2C(C)=C1S(=O)(=O)C=1C=CC(=O)NN=1 NTJWJLZMOKBOFA-UHFFFAOYSA-N 0.000 claims 1
- CABVMWOKBSURKS-UHFFFAOYSA-N 3-[(3-hydroxy-1-benzofuran-2-yl)sulfonyl]-1h-pyridazin-6-one Chemical compound O1C2=CC=CC=C2C(O)=C1S(=O)(=O)C=1C=CC(=O)NN=1 CABVMWOKBSURKS-UHFFFAOYSA-N 0.000 claims 1
- HTJQFBOZQJFYDR-UHFFFAOYSA-N 3-[(3-methyl-1-benzofuran-2-yl)sulfonyl]-1h-pyridazin-6-one Chemical compound O1C2=CC=CC=C2C(C)=C1S(=O)(=O)C=1C=CC(=O)NN=1 HTJQFBOZQJFYDR-UHFFFAOYSA-N 0.000 claims 1
- YWFVMRGAGDNRMA-UHFFFAOYSA-N 3-[(3-phenyl-1-benzofuran-2-yl)sulfonyl]-1h-pyridazin-6-one Chemical compound N1C(=O)C=CC(S(=O)(=O)C2=C(C3=CC=CC=C3O2)C=2C=CC=CC=2)=N1 YWFVMRGAGDNRMA-UHFFFAOYSA-N 0.000 claims 1
- OLKIXQGJDUXXTC-UHFFFAOYSA-N 3-[(5,7-dichloro-1-benzofuran-2-yl)sulfonyl]-1h-pyridazin-6-one Chemical compound C=1C2=CC(Cl)=CC(Cl)=C2OC=1S(=O)(=O)C=1C=CC(=O)NN=1 OLKIXQGJDUXXTC-UHFFFAOYSA-N 0.000 claims 1
- ZDIDXSOYTUCPQE-UHFFFAOYSA-N 3-[(5-chloro-1-benzofuran-2-yl)sulfonyl]-1h-pyridazin-6-one Chemical compound C=1C2=CC(Cl)=CC=C2OC=1S(=O)(=O)C=1C=CC(=O)NN=1 ZDIDXSOYTUCPQE-UHFFFAOYSA-N 0.000 claims 1
- WGSUFIBFKNDTGJ-UHFFFAOYSA-N 3-[(5-chloro-1h-indol-2-yl)sulfonyl]-1h-pyridazin-6-one Chemical compound C=1C2=CC(Cl)=CC=C2NC=1S(=O)(=O)C=1C=CC(=O)NN=1 WGSUFIBFKNDTGJ-UHFFFAOYSA-N 0.000 claims 1
- DDADXEQGUNIKPT-UHFFFAOYSA-N 3-[(5-chloro-3-ethyl-1-benzofuran-2-yl)sulfonyl]-1h-pyridazin-6-one Chemical compound O1C2=CC=C(Cl)C=C2C(CC)=C1S(=O)(=O)C=1C=CC(=O)NN=1 DDADXEQGUNIKPT-UHFFFAOYSA-N 0.000 claims 1
- MDZSNXLRKIMZRY-UHFFFAOYSA-N 3-[(5-chloro-3-hydroxy-1-benzofuran-2-yl)sulfonyl]-1h-pyridazin-6-one Chemical compound O1C2=CC=C(Cl)C=C2C(O)=C1S(=O)(=O)C=1C=CC(=O)NN=1 MDZSNXLRKIMZRY-UHFFFAOYSA-N 0.000 claims 1
- CYXNLUKXQVTYHT-UHFFFAOYSA-N 3-[(5-chloro-3-methyl-1-benzofuran-2-yl)sulfanyl]-6-methoxypyridazine Chemical compound N1=NC(OC)=CC=C1SC1=C(C)C2=CC(Cl)=CC=C2O1 CYXNLUKXQVTYHT-UHFFFAOYSA-N 0.000 claims 1
- GTSQOJISPPCBEE-UHFFFAOYSA-N 3-[(5-chloro-3-methyl-1-benzofuran-2-yl)sulfinyl]-6-methoxypyridazine Chemical compound N1=NC(OC)=CC=C1S(=O)C1=C(C)C2=CC(Cl)=CC=C2O1 GTSQOJISPPCBEE-UHFFFAOYSA-N 0.000 claims 1
- PESVWIXUZNFVOB-UHFFFAOYSA-N 3-[(5-chloro-3-methyl-1-benzofuran-2-yl)sulfonyl]-6-methoxypyridazine Chemical compound N1=NC(OC)=CC=C1S(=O)(=O)C1=C(C)C2=CC(Cl)=CC=C2O1 PESVWIXUZNFVOB-UHFFFAOYSA-N 0.000 claims 1
- JOGGJDKLNQCAQJ-UHFFFAOYSA-N 3-[(5-chloro-3-methyl-1-benzothiophen-2-yl)sulfonyl]-1h-pyridazin-6-one Chemical compound S1C2=CC=C(Cl)C=C2C(C)=C1S(=O)(=O)C=1C=CC(=O)NN=1 JOGGJDKLNQCAQJ-UHFFFAOYSA-N 0.000 claims 1
- MVDAJCXOQBRPQC-UHFFFAOYSA-N 3-[(5-chloro-3-propan-2-yl-1-benzofuran-2-yl)sulfonyl]-1h-pyridazin-6-one Chemical compound O1C2=CC=C(Cl)C=C2C(C(C)C)=C1S(=O)(=O)C=1C=CC(=O)NN=1 MVDAJCXOQBRPQC-UHFFFAOYSA-N 0.000 claims 1
- BVGVSUYAYNIIGE-UHFFFAOYSA-N 3-[(5-fluoro-3-methyl-1-benzofuran-2-yl)sulfonyl]-1h-pyridazin-6-one Chemical compound O1C2=CC=C(F)C=C2C(C)=C1S(=O)(=O)C=1C=CC(=O)NN=1 BVGVSUYAYNIIGE-UHFFFAOYSA-N 0.000 claims 1
- QSROOXVEHSOUBU-UHFFFAOYSA-N 3-[(5-methyl-1-benzothiophen-2-yl)sulfonyl]-1h-pyridazin-6-one Chemical compound C=1C2=CC(C)=CC=C2SC=1S(=O)(=O)C=1C=CC(=O)NN=1 QSROOXVEHSOUBU-UHFFFAOYSA-N 0.000 claims 1
- YCAYZFGZUUVLMY-UHFFFAOYSA-N 3-[(6-chloro-1h-indol-2-yl)sulfonyl]-1h-pyridazin-6-one Chemical compound N1C2=CC(Cl)=CC=C2C=C1S(=O)(=O)C=1C=CC(=O)NN=1 YCAYZFGZUUVLMY-UHFFFAOYSA-N 0.000 claims 1
- VTAPFQFGVVPFNM-UHFFFAOYSA-N 3-[(6-chloro-3-methyl-1-benzofuran-2-yl)sulfonyl]-1h-pyridazin-6-one Chemical compound O1C2=CC(Cl)=CC=C2C(C)=C1S(=O)(=O)C=1C=CC(=O)NN=1 VTAPFQFGVVPFNM-UHFFFAOYSA-N 0.000 claims 1
- PGWALDLWZWXTRU-UHFFFAOYSA-N 3-[(6-fluoro-1h-indol-2-yl)sulfonyl]-1h-pyridazin-6-one Chemical compound N1C2=CC(F)=CC=C2C=C1S(=O)(=O)C=1C=CC(=O)NN=1 PGWALDLWZWXTRU-UHFFFAOYSA-N 0.000 claims 1
- VOZMFKBTMUXWCT-UHFFFAOYSA-N 3-[(7-chloro-1h-indol-2-yl)sulfonyl]-1h-pyridazin-6-one Chemical compound N1C=2C(Cl)=CC=CC=2C=C1S(=O)(=O)C=1C=CC(=O)NN=1 VOZMFKBTMUXWCT-UHFFFAOYSA-N 0.000 claims 1
- GJSIXQDXGNTUSN-UHFFFAOYSA-N 3-[[3-(4-fluorophenyl)-1-benzofuran-2-yl]sulfonyl]-1h-pyridazin-6-one Chemical compound C1=CC(F)=CC=C1C1=C(S(=O)(=O)C2=NNC(=O)C=C2)OC2=CC=CC=C12 GJSIXQDXGNTUSN-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- GCNTZFIIOFTKIY-UHFFFAOYSA-N 4-hydroxypyridine Chemical compound OC1=CC=NC=C1 GCNTZFIIOFTKIY-UHFFFAOYSA-N 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 claims 1
- KOMHRWJUPOOMDU-UHFFFAOYSA-N ClC=1C=CC2=C(C(=C(O2)S(=O)(=O)C=2C=CC(NN2)=O)C)C1.[Na] Chemical compound ClC=1C=CC2=C(C(=C(O2)S(=O)(=O)C=2C=CC(NN2)=O)C)C1.[Na] KOMHRWJUPOOMDU-UHFFFAOYSA-N 0.000 claims 1
- 208000002249 Diabetes Complications Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004534 benzothien-2-yl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- CJXGPJZUDUOZDX-UHFFFAOYSA-N fluoromethanone Chemical group F[C]=O CJXGPJZUDUOZDX-UHFFFAOYSA-N 0.000 claims 1
- 210000005003 heart tissue Anatomy 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 claims 1
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims 1
- 125000004536 indazol-1-yl group Chemical group N1(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000002249 indol-2-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([*])=C([H])C2=C1[H] 0.000 claims 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28005101P | 2001-03-30 | 2001-03-30 | |
| PCT/IB2002/000320 WO2002079198A1 (en) | 2001-03-30 | 2002-01-31 | Pyridazinone aldose reductase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004528319A JP2004528319A (ja) | 2004-09-16 |
| JP2004528319A5 true JP2004528319A5 (enExample) | 2006-01-05 |
Family
ID=23071435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002577823A Pending JP2004528319A (ja) | 2001-03-30 | 2002-01-31 | ピリダジノンアルドースレダクダーゼ阻害物質 |
Country Status (43)
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
| US11718589B2 (en) | 2017-02-06 | 2023-08-08 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase |
| US12336982B2 (en) | 2018-11-21 | 2025-06-24 | Rodeo Therapeutics Corporation | Compositions and methods of modulating short-chain dehydrogenase activity |
| US12616681B2 (en) | 2019-04-04 | 2026-05-05 | Case Western Reserve University | Compositions and methods for treating renal injury |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6001876A (en) | 1996-07-24 | 1999-12-14 | Warner-Lambert Company | Isobutylgaba and its derivatives for the treatment of pain |
| ES2240657T3 (es) * | 2001-02-28 | 2005-10-16 | Pfizer Products Inc. | Compuestos de sulfonilpiridazinona utiles como inhibidores de aldosa reductasa. |
| ATE348100T1 (de) * | 2001-03-30 | 2007-01-15 | Pfizer Prod Inc | Zwischenprodukten für die herstellung von pyridazinon aldose reductase inhibitoren. |
| AU761191B2 (en) * | 2001-05-24 | 2003-05-29 | Pfizer Products Inc. | Therapies for tissue damage resulting from ischemia |
| CN1269814C (zh) | 2002-01-09 | 2006-08-16 | 辉瑞产品公司 | 哒嗪酮抗糖尿病药的制备方法和中间体 |
| US20040092522A1 (en) * | 2002-08-15 | 2004-05-13 | Field Mark John | Synergistic combinations |
| US7419981B2 (en) * | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
| US6872833B2 (en) * | 2003-04-14 | 2005-03-29 | Hoffmann-La Roche Inc. | Adenosine receptor ligands |
| US8017634B2 (en) | 2003-12-29 | 2011-09-13 | President And Fellows Of Harvard College | Compositions for treating obesity and insulin resistance disorders |
| US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| CA2568640C (en) | 2004-06-04 | 2011-08-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| US20060035251A1 (en) * | 2004-06-30 | 2006-02-16 | Whitehead Institute For Biomedical Research | Novel methods for high-throughput genome-wide location analysis |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| BRPI0706523A2 (pt) * | 2006-01-13 | 2011-01-04 | Wyeth Corp | composto de fórmula i; composição farmacêutica; método de tratamento de distúrbios que estão relacionados com ou são afetados pela inibição da recaptação de norepinefrina, o receptor de 5-ht6 ou o receptor de 5-ht2a; método de tratamento de um distúrbio de aprendizado, de um distúrbio cognitivo, de um distúrbio de memória, de um distúrbio de personalidade, de um distúrbio comportamental, de um distúrbio de movimento, de um distúrbio neurodegenerativo, de abstinência de droga, de distúrbio de sono, de um distúrbio alimentar, de uma toxicidade de droga aguda, de um distúrbio cardiovascular, de uma disfunção sexual, de um distúrbio gastrintestinal, de um distúrbio genitourinário, de um distúrbio de dor, de um distúrbio nervoso ou de um distúrbio de sintoma vasomotor; método de tratamento de doença de alzheimer, de um distúrbio de deficiência da atenção, de esquizofrenia, de doença de parkinson, de discinésia tardia, de ataxia, de bradicinésia, de discinésias paroxìsmicas, de sìndrome da perna irrequieta, de tremor, de tremor essencial, de epilepsia, de apoplexia ou de trauma na cabeça; método de tratamento de doença arterial coronariana, de enfarte do miocárdio, de ataque isquêmico transitório, de angina, de fibrilação atrial, de agregação plaquetária, de risco de formação de coágulo sanguìneo, de sìndrome do intestino irritável, de constipação crÈnica, de doença do refluxo gastrintestinal, de dispepsia, de incontinência urinária por estresse ou de incontinência urinária de urgência; método de tratamento de depressão, de distúrbio compulsivo obsessivo, de tendência ao suicìdio, de distúrbio de ansiedade, de distúrbio bipolar, de distúrbio de pánico, de abstinência de nicotina, de abstinência de álcool, de abstinência de cocaìna, de abstinência de heroìna, de abstinência de anfetamina, de abstinência de drogas narcóticas, de insÈnia, de apnéia do sono, de narcolepsia, de distúrbio afetivo sanzonal, de sìndrome da perna irrequieta, de distúrbio de sono de turno de trabalho, de sìndrome da fase do sono retardada, de anorexia nervosa, de bulimia nervosa, de sìndrome do comer noturno, de superalimentação compulsiva, de sìndrome da fadiga crÈnica, de fibromialgia, de neuropatia de dor, de dor antinociceptiva, de sìndrome da dor crÈnica, de neuropatia diabética, de fogacho ou de suor noturno; e uso de um composto |
| CL2007001873A1 (es) * | 2006-06-27 | 2008-01-04 | Takeda Pharmaceutical | Acido((3s))-6-((¨2,6-dimetil-4-(3-(metilsulfonil)-propoxi)bifenil-3-il)metoxi-2,3-dihidro-1-benzofuran-3-il)acetico o una sal del mismo |
| JP5498168B2 (ja) | 2006-12-01 | 2014-05-21 | ブリストル−マイヤーズ スクイブ カンパニー | アテローム性動脈硬化および循環器疾患の治療のためのｃｅｔｐ阻害剤としてのｎ−（（３−ベンジル）−２，２−（ビス−フェニル）−プロパン−１−アミン誘導体 |
| WO2008116107A2 (en) * | 2007-03-21 | 2008-09-25 | Takeda San Diego, Inc. | Piperazine derivatives as glucokinase activators |
| SG176464A1 (en) | 2008-05-09 | 2011-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| EP2509596B1 (en) | 2009-12-08 | 2019-08-28 | Case Western Reserve University | Gamma aminoacids for treating ocular disorders |
| US8916563B2 (en) | 2010-07-16 | 2014-12-23 | The Trustees Of Columbia University In The City Of New York | Aldose reductase inhibitors and uses thereof |
| CA2848877A1 (en) * | 2011-09-15 | 2013-03-21 | Taipei Medical University | Use of indolyl and indolinvl hvdroxamates for treating heart failure or neuronal injury |
| US9339542B2 (en) * | 2013-04-16 | 2016-05-17 | John L Couvaras | Hypertension reducing composition |
| SG11201507496UA (en) | 2013-04-17 | 2015-11-27 | Pfizer | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| CN103739547B (zh) * | 2014-01-03 | 2015-09-02 | 沈阳药科大学 | 2-[6-甲氧基-3-(2,3-二氯苯基)甲基-4-氧代-1,4-二氢-1(4h)-喹啉基]乙酸的合成方法 |
| WO2016055901A1 (en) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Substituted amide compounds |
| JP2018511616A (ja) * | 2015-04-14 | 2018-04-26 | ケース ウエスタン リザーブ ユニバーシティ | 短鎖デヒドロゲナーゼ活性を調節する組成物および方法 |
| WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
| IL283809B2 (en) | 2016-06-21 | 2024-01-01 | Univ Columbia | Compounds for use in a method of treating neuropathy, retinopathy, nephropathy, or cardiomyopathy |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
| US10344002B2 (en) | 2016-09-26 | 2019-07-09 | Nusirt Sciences, Inc. | Compositions and methods for treating metabolic disorders |
| IL272246B2 (en) | 2017-07-28 | 2026-01-01 | Applied Therapeutics Inc | History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications |
| US11248001B2 (en) | 2019-01-18 | 2022-02-15 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| AU2020254610A1 (en) | 2019-04-01 | 2021-11-18 | Applied Therapeutics Inc. | Inhibitors of aldose reductase |
| CN113966396A (zh) | 2019-05-07 | 2022-01-21 | 迈阿密大学 | 遗传性神经病和相关障碍的治疗和检测 |
| US11274082B2 (en) | 2019-05-31 | 2022-03-15 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| WO2020243423A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| WO2022120353A1 (en) * | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE47592B1 (en) | 1977-12-29 | 1984-05-02 | Ici Ltd | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture |
| US4939140A (en) | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
| US4996204A (en) | 1989-05-11 | 1991-02-26 | Pfizer Inc. | Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors |
| FR2647676A1 (fr) | 1989-06-05 | 1990-12-07 | Union Pharma Scient Appl | Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase |
| EP0516860A4 (en) * | 1990-11-30 | 1993-12-01 | Tsumura & Co. | Chromone derivative and aldose reductase inhibitor containing the same as active ingredient |
| CZ387092A3 (en) | 1991-03-28 | 1994-02-16 | Pfizer | Pyridazinoacetic acids, their derivatives, process of their preparation and use |
| US5834466A (en) | 1994-12-22 | 1998-11-10 | The Regents Of The University Of California | Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia |
| TW438587B (en) | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| TR200000764T2 (tr) * | 1997-09-24 | 2001-03-21 | Orion Corporation | Fosfolamban inhibitörleri olarak, 1-okza, aza ve tiyanaftalin-2-on'ların biseterleri. |
| FR2822827B1 (fr) * | 2001-03-28 | 2003-05-16 | Sanofi Synthelabo | Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant |
| ATE348100T1 (de) * | 2001-03-30 | 2007-01-15 | Pfizer Prod Inc | Zwischenprodukten für die herstellung von pyridazinon aldose reductase inhibitoren. |
| AU2002236131B2 (en) * | 2001-04-30 | 2005-04-14 | Pfizer Products Inc. | Combinations of aldose reductase inhibitors and cyclooxygenase-2 inhibitors |
| CN1269814C (zh) * | 2002-01-09 | 2006-08-16 | 辉瑞产品公司 | 哒嗪酮抗糖尿病药的制备方法和中间体 |
-
2002
- 2002-01-31 AT AT04023149T patent/ATE348100T1/de not_active IP Right Cessation
- 2002-01-31 ES ES02716247T patent/ES2231681T3/es not_active Expired - Lifetime
- 2002-01-31 AT AT02716247T patent/ATE286049T1/de active
- 2002-01-31 SK SK1185-2003A patent/SK11852003A3/sk unknown
- 2002-01-31 HU HU0303644A patent/HUP0303644A3/hu unknown
- 2002-01-31 CA CA002442476A patent/CA2442476A1/en not_active Abandoned
- 2002-01-31 EP EP04023150A patent/EP1491541B1/en not_active Expired - Lifetime
- 2002-01-31 DK DK02716247T patent/DK1373259T3/da active
- 2002-01-31 PT PT04023149T patent/PT1491540E/pt unknown
- 2002-01-31 NZ NZ528406A patent/NZ528406A/en unknown
- 2002-01-31 BR BR0208571-2A patent/BR0208571A/pt not_active IP Right Cessation
- 2002-01-31 EP EP02716247A patent/EP1373259B1/en not_active Expired - Lifetime
- 2002-01-31 PL PL02365294A patent/PL365294A1/xx not_active Application Discontinuation
- 2002-01-31 CN CNB028076001A patent/CN1215067C/zh not_active Expired - Fee Related
- 2002-01-31 SI SI200230071T patent/SI1373259T1/xx unknown
- 2002-01-31 JP JP2002577823A patent/JP2004528319A/ja active Pending
- 2002-01-31 ES ES04023149T patent/ES2274369T3/es not_active Expired - Lifetime
- 2002-01-31 DK DK04023149T patent/DK1491540T3/da active
- 2002-01-31 YU YU71403A patent/YU71403A/sh unknown
- 2002-01-31 EP EP04023149A patent/EP1491540B1/en not_active Expired - Lifetime
- 2002-01-31 GE GE5314A patent/GEP20053675B/en unknown
- 2002-01-31 PT PT02716247T patent/PT1373259E/pt unknown
- 2002-01-31 EE EEP200300470A patent/EE200300470A/xx unknown
- 2002-01-31 AT AT04023150T patent/ATE352551T1/de not_active IP Right Cessation
- 2002-01-31 UA UA2003098846A patent/UA73236C2/uk unknown
- 2002-01-31 HR HR20030752A patent/HRP20030752A2/hr not_active Application Discontinuation
- 2002-01-31 DE DE60202452T patent/DE60202452C5/de not_active Expired - Fee Related
- 2002-01-31 OA OA1200300222A patent/OA12453A/en unknown
- 2002-01-31 WO PCT/IB2002/000320 patent/WO2002079198A1/en not_active Ceased
- 2002-01-31 DE DE60216823T patent/DE60216823T2/de not_active Expired - Fee Related
- 2002-01-31 IL IL15646202A patent/IL156462A0/xx unknown
- 2002-01-31 MX MXPA03008850A patent/MXPA03008850A/es active IP Right Grant
- 2002-01-31 DE DE60217930T patent/DE60217930T2/de not_active Expired - Fee Related
- 2002-01-31 EA EA200300673A patent/EA006023B1/ru not_active IP Right Cessation
- 2002-01-31 KR KR1020037012753A patent/KR100586138B1/ko not_active Expired - Fee Related
- 2002-01-31 AU AU2002226634A patent/AU2002226634B2/en not_active Ceased
- 2002-03-21 US US10/104,664 patent/US6579879B2/en not_active Expired - Fee Related
- 2002-03-22 PA PA20028541801A patent/PA8541801A1/es unknown
- 2002-03-27 AR ARP020101134A patent/AR035798A1/es unknown
- 2002-03-27 MY MYPI20021093A patent/MY134304A/en unknown
- 2002-03-27 UY UY27237A patent/UY27237A1/es not_active Application Discontinuation
- 2002-03-27 PE PE2002000246A patent/PE20030007A1/es not_active Application Discontinuation
- 2002-03-28 AP APAP/P/2002/002461A patent/AP2002002461A0/en unknown
- 2002-03-29 TN TNTNSN02037A patent/TNSN02037A1/fr unknown
- 2002-03-29 TW TW091106386A patent/TWI245762B/zh not_active IP Right Cessation
- 2002-03-31 CZ CZ20032563A patent/CZ20032563A3/cs unknown
-
2003
- 2003-02-20 US US10/370,895 patent/US6849629B2/en not_active Expired - Fee Related
- 2003-06-16 IS IS6845A patent/IS2205B/is unknown
- 2003-06-17 ZA ZA200304671A patent/ZA200304671B/en unknown
- 2003-06-25 EC EC2003004671A patent/ECSP034671A/es unknown
- 2003-09-17 BG BG108179A patent/BG108179A/xx unknown
- 2003-09-17 MA MA27314A patent/MA27003A1/fr unknown
- 2003-09-29 NO NO20034345A patent/NO20034345L/no unknown
-
2006
- 2006-01-23 IS IS8251A patent/IS8251A/is unknown
- 2006-01-23 IS IS8250A patent/IS8250A/is unknown
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
| US11718589B2 (en) | 2017-02-06 | 2023-08-08 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase |
| US12336982B2 (en) | 2018-11-21 | 2025-06-24 | Rodeo Therapeutics Corporation | Compositions and methods of modulating short-chain dehydrogenase activity |
| US12616681B2 (en) | 2019-04-04 | 2026-05-05 | Case Western Reserve University | Compositions and methods for treating renal injury |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60202452C5 (de) | Pyridazinonaldose reductase inhibitoren | |
| US6869943B2 (en) | Sorbitol dehydrogenase inhibitors | |
| KR100922538B1 (ko) | 2,4,5-삼치환된 티아졸릴 유도체 및 그의 항염증성 활성 | |
| US8993598B2 (en) | Pyrrole compounds | |
| EP1753743B1 (en) | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals | |
| JP5331693B2 (ja) | 新規置換ビピリジン誘導体およびアデノシン受容体リガンドとしてのそれらの使用 | |
| JP2013505913A (ja) | Ｃｒａｃ調節剤としてのインドール誘導体 | |
| JP2012525335A5 (enExample) | ||
| KR20100092909A (ko) | 잔틴 옥시다제 저해제로서 효과적인 신규 화합물, 그 제조방법 및 그를 함유하는 약제학적 조성물 | |
| ZA200406225B (en) | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof | |
| JP2009536617A (ja) | タンパク質キナーゼの阻害剤として有用なチアゾール、イミダゾール、およびピラゾール | |
| AU2002341921A1 (en) | Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 | |
| EP1434773A2 (en) | Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 | |
| JP2002523511A5 (enExample) | ||
| EP2509975A1 (en) | Benzimidazole inhibitors of leukotriene production | |
| KR20100076043A (ko) | 2-아미노-4,5-삼치환 티아졸릴 유도체 | |
| JP2020536116A5 (enExample) | ||
| CA2315117A1 (en) | Heterocyclic ether and thioether compounds useful in controlling chemical synaptic transmission | |
| JP2011529959A5 (enExample) | ||
| WO2007063928A1 (ja) | 新規な非環状アミンカルボキシアミド誘導体及びその塩 | |
| WO2002008225A1 (en) | 2-(1h-indol-3-yl)-2-oxo-acetic acid amides with antitumor activity | |
| JP2012522806A (ja) | 抗ウイルス処置のためのインドール誘導体および方法 | |
| ZA200307204B (en) | Combinations of aldose reductase inhibitors and cyclooxygenase-2-inhibitors. | |
| CN101253168A (zh) | 作为激酶抑制剂的被取代的苯并咪唑类物质 | |
| JP2005232149A (ja) | ４−ピリジルアルキルチオ基を置換基として有する新規化合物 |